Table 2.
Baseline characteristics of the study population.
| N = 172 | |
|---|---|
| n (%) | |
| Age, years (IQR) | 54 (43.7–65) |
| 21–40 | 32 (18.7) |
| 41–50 | 41 (23.8) |
| 51–65 | 53 (30.8) |
| >65 | 46 (26.7) |
| Gender | |
| Female | 96 (55.8) |
| Male | 76 (44.2) |
| BMI, kg/m2 | 26 (22.5–29) |
| Lung disease | |
| Not present | 144 (83.4) |
| Minimal use of inhalers | 10 (5.9) |
| Frequent use of inhalers | 18 (10.7) |
| Obstructive sleep apnea | |
| Not present | 141 (81.9) |
| Mild to moderate, without CPAP use | 18 (10.5) |
| Use of CPAP | 13 (7.6) |
| Cardiovascular disease | |
| Not present | 89 (51.8) |
| Minimal, no medication | 16 (9.4) |
| Mild, 1 medication | 31 (18) |
| Moderate, 2 medications | 29 (16.8) |
| Severe, 3 or more medications | 7 (4) |
| Diabetes mellitus | |
| Not present | 93 (54) |
| Mild, no medications | 8 (4.7) |
| Moderate, only oral medications | 46 (26.8) |
| Severe, insulin use | 17 (9.8) |
| No data | 8 (4.7) |
| Immunocompromise | |
| Not present | 105 (61.1) |
| Mild | 6 (3.4) |
| Moderate | 33 (19.2) |
| Severe | 25 (14.6) |
| No data | 3 (1.7) |
| Respiratory symptoms | |
| Asymptomatic | 158 (91.8) |
| Yes | 6 (3.5) |
| No data | 8 (4.7) |
| Exposure to COVID-positive person in previous 14 days | |
| No | 141 (81.9) |
| Not likely | 23 (13.4) |
| Possibly | 8 (4.7) |
BMI: body mass index; CPAP: continuous positive airway pressure.